1 / 44

Hepatitis-2015 Orlando, USA July 20 - 22 2015

Hepatitis-2015 Orlando, USA July 20 - 22 2015. Parveen Malhotra. Epidemiological Profile Of Patients At a New Hub Of Hepatitis C in India. Dr. PARVEEN MALHOTRA MD,DNB (GASTRO),MNAMS,FIACM,FICP,PGDD PROFESSOR & HEAD DEPTT. OF MEDICAL GASTROENTEROLOGY PGIMS, ROHTAK.

taylor
Download Presentation

Hepatitis-2015 Orlando, USA July 20 - 22 2015

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hepatitis-2015Orlando, USAJuly 20 - 22 2015 Parveen Malhotra

  2. Epidemiological Profile Of Patients At a New Hub Of Hepatitis C in India Dr. PARVEEN MALHOTRA MD,DNB (GASTRO),MNAMS,FIACM,FICP,PGDD PROFESSOR & HEAD DEPTT. OF MEDICAL GASTROENTEROLOGY PGIMS, ROHTAK

  3. THE CULPRIT- NO VACCINATION

  4. REAL CAUSE FOR FIGHT

  5. Sources of Infection for Persons with Hepatitis C Sexual 15% Transfusion 10% (before screening) *Nosocomial; Health-care work; Perinatal Other* 5% Injecting drug use 60% Unknown 10% Source: Centers for Disease Control and Prevention Source: Sentinel Counties, CDC

  6. Indian Scenario • Nearly 12.5 million Indians are suffering from Hepatitis C affecting the liver. • Over one lakh people get infected every year in India, according to the Indian National Association for the Study of Liver (INASL) study. • Every 15th carrier of the HCV is an Indian, according to a recent report and it is responsible for as many as one in four cases of liver cancer and chronic liver disease.

  7. HARYANA SCENARIO • Initially in Haryana , the prevalence of Chronic hepatitis C was thought to be comparable to other parts of India. • Now the prevalence has drastically increased and is reaching the levels of areas with high incidence like Manipur and Punjab. • There are certain districts like Jind , Kaithal, Fatehabad, Panipat, Karnal and Sonepat where Prevalence is touching even 40-50%.

  8. GOOD NEWS FOR HARYANA • Haryana has become the first state of India where a separate, dedicated centre has been started under Department of Medical Gastroenterology, PGIMS, Rohtak. • Free treatment of Chronic Hepatitis C has been started for patients belonging to BPL/SC and at subsidized rates for general population. •  Twenty thousand patients have been screened over different parts of haryana.

  9. HEALTH TALKS

  10. HEALTH LECTURES

  11. MEDIA INTERACTIONS

  12. BILONA VILLAGE

  13. AWARENESS TALK AT DERAS

  14. DHABI TEK SINGH VILLAGE

  15. Patients were treated with standard doses of Pegylated Interferon and Ribavarin. • Up till now 1500 patients have completed treatment. • At present 1500 more patients are currently on treatment.

  16. GENDER DISTRIBUTION

  17. DEMOGRAPHICAL PROFILE

  18. MARITAL STATUS

  19. AGE DISTRIBUTION

  20. DISTRICT WISE DISTRIBUTION

  21. RISK FACTORS

  22. SYMPTOMATOLOGY

  23. GENOTYPE DISTRIBUTION

  24. SIDE EFFECTS

  25. VIROLOGICAL RESPONSE

  26. COMPLIANCE RATE

  27. HEPATITIS C HELPLINE 08950012900

  28. CHEER LEADERS

  29. CHEER COUPLE

  30. ACTIVE ROLE OF NGO’S

  31. AWARENESS BY STAFF

  32. MOTIVATION FROM TOP

  33. SOFOSBUVIR- A NEW HOPE • Up till now 200 patients have been put on treatment • Majority are on Triple therapy • Dual therapy – Decompensated cirrhotic or on patient will • RVR has been achieved in 95% of patients • Excellent Compliance rate

  34. CONCLUSIONS • Haryana has become new hub of Chronic hepatitis C in India. • Majority of patients are male and belong to young age group i.e. 20-40 years of age group. • Genotype 3 most common and Genotype 4 is more common in comparison to other parts of Northern India. • Most common side effects- A.N. & Depression, Dyspepsia, Weight loss, Malaise, Generalized weakness. • Good compliance and success rates are being achieved.

  35. TAKE HOME MESSAGE • Most important and first step is appreciation of problem. • Next step is to prioritize resources in more prevalent areas. • Development of Vaccine and Interferon free regimen is future dream for hepatitis C. • Regular Screening camps and awareness in society is utmost need of hour to curb the menace of this disease. • Do not wait till all resources are compiled- Start moving.

  36. RATIONALE BASED TREATMENT • Pseudo belief on Alternative Medicines. • Anti HCV Vs HCV RNA based

  37. ECONOMICAL TREATMENT STRATEGIES • SCIENTIFIC AND RATIONALE BASED TREATMENT • ROLE OF TREATING PHYSICIANS • ROLE OF STATE AND CENTER • ROLE OF NGO’S • ROLE OF PHARMACEUTICAL COMPANIES • ROLE OF MEDIA AND GENERAL POPULATION

  38. Meet the eminent gathering once again atHepatitis-2016Dubai, UAEOctober 17 - 19, 2016 Hepatitis– 2016 Website: hepatitis.omicsgroup.com

More Related